BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1424 related articles for article (PubMed ID: 16249072)

  • 1. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
    Tamura K
    Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial therapy of unexplained fever in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society).
    Link H; Böhme A; Cornely OA; Höffken K; Kellner O; Kern WV; Mahlberg R; Maschmeyer G; Nowrousian MR; Ostermann H; Ruhnke M; Sezer O; Schiel X; Wilhelm M; Auner HW; ;
    Ann Hematol; 2003 Oct; 82 Suppl 2():S105-17. PubMed ID: 13680173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of the febrile neutropenic patient.
    Picazo JJ;
    Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S120-2; discussion S133-40. PubMed ID: 16243492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antimicrobial prophylaxis and therapy in neutropenia].
    Link H
    Mycoses; 2003; 46 Suppl 2():21-32. PubMed ID: 15055140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia.
    Tamura K; Imajo K; Akiyama N; Suzuki K; Urabe A; Ohyashiki K; Tanimoto M; Masaoka T;
    Clin Infect Dis; 2004 Jul; 39 Suppl 1():S15-24. PubMed ID: 15250016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial empirical antimicrobial therapy: duration and subsequent modifications.
    Tamura K
    Clin Infect Dis; 2004 Jul; 39 Suppl 1():S59-64. PubMed ID: 15250024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparative study.
    Tamura K; Matsuoka H; Tsukada J; Masuda M; Ikeda S; Matsuishi E; Kawano F; Izumi Y; Uike N; Utsunomiya A; Saburi Y; Shibuya T; Imamura Y; Hanada S; Okamura S; Gondoh H;
    Am J Hematol; 2002 Dec; 71(4):248-55. PubMed ID: 12447952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of fever in neutropenic patients with different risks of complications.
    Klastersky J
    Clin Infect Dis; 2004 Jul; 39 Suppl 1():S32-7. PubMed ID: 15250018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical guidelines for the management of cancer patients with neutropenia and unexplained fever.
    Jun HX; Zhixiang S; Chun W; Reksodiputro AH; Ranuhardy D; Tamura K; Matsumoto T; Lee DG; Purushotaman SV; Lim V; Ahmed A; Hussain Y; Chua M; Ong A; Liu CY; Hsueh PR; Lin SF; Liu YC; Suwangool P; Jootar S; Picazo JJ
    Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S128-32; discussion S133-40. PubMed ID: 16253480
    [No Abstract]   [Full Text] [Related]  

  • 10. Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors.
    Oguz A; Karadeniz C; Citak EC; Cil V; Eldes N
    Pediatr Hematol Oncol; 2006; 23(3):245-53. PubMed ID: 16517540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
    Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
    Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime.
    Raad II; Escalante C; Hachem RY; Hanna HA; Husni R; Afif C; Boktour MR; Whimbey EE; Kontoyiannis D; Jacobson K; Kantarjian H; Levett LM; Rolston KV
    Cancer; 2003 Sep; 98(5):1039-47. PubMed ID: 12942573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefepime monotherapy is as effective as ceftriaxone plus amikacin in pediatric patients with cancer and high-risk febrile neutropenia in a randomized comparison.
    Pereira CA; Petrilli AS; Carlesse FA; Luisi FA; da Silva KV; de Martino Lee ML
    J Microbiol Immunol Infect; 2009 Apr; 42(2):141-7. PubMed ID: 19597646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cefepime plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients.
    Hamidah A; Lim YS; Zulkifli SZ; Zarina AL; Nordiah AJ; Jamal R
    Singapore Med J; 2007 Jul; 48(7):615-9. PubMed ID: 17609821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Application of the concepts of evidence-based medicine to the evidence on the treatment of febrile neutropenia].
    Jarque I; Sanz MA
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():95-102. PubMed ID: 10605194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Panipenem versus cefepime as empirical monotherapy in adult cancer patients with febrile neutropenia: a prospective randomized trial.
    Kwon KT; Cheong HS; Rhee JY; Wi YM; Ryu SY; Heo ST; Moon CS; Ki HK; Kim KH; Jung CW; Peck KR; Song JH
    Jpn J Clin Oncol; 2008 Jan; 38(1):49-55. PubMed ID: 18203711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapy of febrile neutropenia episodes in systemic hematologic illnesses with new once daily ceftriaxone administration].
    Karthaus M; Südhoff T; Fenchel K; Egerer G; Kämpfe D; Ritter J; Franke A; Heil G; Peters G; Jürgens H
    Wien Med Wochenschr; 1998; 148(21):481-7. PubMed ID: 10048176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy.
    Freifeld A; Marchigiani D; Walsh T; Chanock S; Lewis L; Hiemenz J; Hiemenz S; Hicks JE; Gill V; Steinberg SM; Pizzo PA
    N Engl J Med; 1999 Jul; 341(5):305-11. PubMed ID: 10423464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empiric monotherapy in neutropenia: a realistic goal?
    Del Favero A; Bucaneve G; Menichetti F
    Scand J Infect Dis Suppl; 1995; 96():34-7. PubMed ID: 7652501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patients.
    Glasmacher A; von Lilienfeld-Toal M; Schulte S; Hahn C; Schmidt-Wolf IG; Prentice A
    Clin Microbiol Infect; 2005 Oct; 11 Suppl 5():17-23. PubMed ID: 16138815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 72.